An innovative therapy and psychedelic-focused company will soon be the subject of a TV segment on a program dedicated to providing viewers with informational and educational content.
On Wednesday, HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) proudly announced that company members would be appearing on an episode of Viewpoint with Dennis Quaid next month. The upcoming installment of the television series will be aired on over 170 public TV stations across the United States, being viewed in an estimated 60 million homes before 2023.
We’re thrilled to be featured in an episode of Viewpoint with Dennis Quaid premiering in July!
The program provides an educational platform & we’re proud to be part of the movement helping to redefine psychedelics in the popular imagination. $HAVN $HAVLF https://t.co/VJ6QRI6Qzt pic.twitter.com/cv0hfOG6RO
— HAVN Life (@HavnLife) June 22, 2022
HAVN Life Sciences is a company dedicated to the pursuit of psychedelic compound extraction and the progression of novel therapies and products that will enhance cognitive abilities and support overall brain health. The company claims that it has developed an end-to-end supply chain of naturally formulated psychedelic compounds for research purposes that will forever alter the future of contemporary medicine.
“From the very start, our mission has been to bring medicine to the people,” said HAVN Chief Psychedelic Officer, Dr. Ivan Casselman.
The Viewpoint Project is a diverse documentary program covering an assortment of intellectual and informative topics. Its creative team emphasizes a desire to improve people’s lives through quality content, locally and internationally.
The development crew there has received over 100 awards through the course of the past 20 years, and features a team of editors, writers, producers and imaging specialists with over a century of cumulative experience.
The Host, Dennis Quaid, is an actor, director and producer who is known for his roles in a broad range of feature films since the early 1980s.
Viewpoint’s upcoming July episode will feature a thorough interview with HAVN CEO, Tim Moore. It will also contain a series of clips from Chief Psychedelic Officer, Dr. Ivan Casselman, and Chief Research Officer, Alexzander Samuelsson, discussing research and development endeavours undertaken by the company, psilocybin and various beneficial partnerships that HAVN has secured.
The segment will additionally cover how HAVN is committed to advancing the field of psychedelic medicine through clinical studies.
“As part of the evolving psychedelic industry, I’m proud of the way HAVN Life has been able to take a leading role in sharing information and perspectives on the history of psychedelics, its usage, and the huge potential that psilocybin-based therapies have to offer. Through our work and partnerships, we are building a pathway to healing and relief for those suffering from mental health issues, which many people have been dealing with during the past two years of pandemic lockdowns, isolation, opportunity and personal losses,” said Alexzander Samuelsson, Chief Research Officer at HAVN Life.
It is also worth mentioning that a recently developed network-quality commercial showcasing natural health products made by the biotechnology company will premiere twice during prime time on Fox Business next month.
Those commercials are anticipated to air up to 400 times before the end of December, broadcasting to approximately 84 million homes on channels such as Discovery, CNBC, The Learning Channel and CNN.